Aquadex SmartFlow® System by Nuwellis Selected as a 2021 R&D 100 Awards Winner
The Aquadex SmartFlow System simply, safely, and precisely removes excess fluid (primarily salt and water) from patients suffering from fluid overload who have not responded to medical management, including diuretics. Providers can specify and adjust the rate of fluid removed for each individual patient, resulting in a gradual reduction of excess fluid. Up to 500 mL per hour of excess fluid can be removed.
The Aquadex system was selected as a recipient of this award specifically for its indication for use. The console received FDA 510(k) clearance in the
“It is an honor to be included among so many terrific companies that have developed technologies that are making positive impacts on people’s lives,” said
Award recipients were announced at a virtual ceremony on Tuesday, October 19, 2021.
About the Aquadex SmartFlow System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and predictable method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
George MontagueChief Financial Officer, Nuwellis, Inc.firstname.lastname@example.org Matt Bacso, CFA Gilmartin Group LLCMatt.email@example.com Media Contact: Laurel HoodHealth+Commerce firstname.lastname@example.org
Source: Nuwellis, Inc.